These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Treatment with LH-RH in female sterility].
    Author: Caron P, Colombo PL, Bennet A, Barousse C, Louvet JP.
    Journal: J Gynecol Obstet Biol Reprod (Paris); 1987; 16(3):373-7. PubMed ID: 3298393.
    Abstract:
    The discovery that LH/RH was secreted in a pulsatile manner has made it possible to use the substance therapeutically in certain endocrine conditions of female sterility. 29 patients had sterility because of ovarian dysfunction. 3 of these were polycystic ovaries, 13 unexplained malfunction of ovulation and 30 hypothalamic in cause. They were treated with LH/RH intravenously. The dose used with each pulse was 6-18 micrograms. The patients were treated for between 18 and 30 days. In the 9 pregnancies that occurred (30%) one was in a patient with polycystic ovaries, 8 (70%) were in patients with hypothalamic ovarian failure. In each case the dose of LH/RH had been administered either at a level of less than 10 micrograms/pulse throughout the follicular phase with an injection of 5000 IU of HCG after ovulation or throughout the whole cycle. 77% of the pregnancies were obtained during the two first cycles of treatment. This work shows that hypothalamic female sterility is the proper indication for treatment using LH/RH. The protocol of dosage should be as economical as possible by administering 5-10 micrograms pulses intravenously up to the time that ovulation has been achieved. This takes note of the difficulties of obtaining supplies of the substance.
    [Abstract] [Full Text] [Related] [New Search]